ArticlePharmacoEconomics2019
Cost Effectiveness of Nusinersen in the Treatment of Patients with Infantile-Onset and Later-Onset Spinal Muscular Atrophy in Sweden.
Santiago Zuluaga-Sanchez et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
41 papers cite it
this paperpooled itcites it